In a bid to expand its manufacturing plant in Scotland, Piramal Healthcare has invested two million pounds. The company is aiming to expand this facility in the next 5 years to maintain its position as a global leader in the production of antibody drug conjugates.
The plant manufactures anti-cancer drugs (antibody drug conjugates) for export. The investment of two million pounds into Scotland will yield additional revenue of 3-5 million pounds over five years to Piramal Healthcare’s revenue.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Healthcare, Healthcare Information Management and Financial Services. Its consolidated revenues were over $830 million in FY2015, with approx. 70% of revenues from outside India.
